SCHEMBL21056702

SCHEMBL21056702

C=Cc1cnccc1C(=O)O

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 18/20 0.53
▸ KDM6B O15054 8/20 0.53
▸ KDM4D Q6B0I6 5/20 0.53
▸ KDM4E B2RXH2 2/20 0.53
▸ KDM4A O75164 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ MEN1 O00255 1/20 0.53
▸ MAPT P10636 1/20 0.53
▸ THRB P10828 1/20 0.53
▸ KMT2A Q03164 1/20 0.53
▸ TDP1 Q9NUW8 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ NAPRT Q6XQN6 1/20 0.39
▸ APP P05067 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HCAR3 P49019 1/20 0.38
▸ HCAR2 Q8TDS4 1/20 0.38
▸ EGLN3 Q9H6Z9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29749311 1.00 KDM4C (0.53) KDM4CKDM6BKDM4DKDM4EKDM4A
Pyrazole SCHEMBL28840140 0.85 KDM4C (0.41) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL547927 0.82 KDM4C (0.55) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL19284336 0.79 KDM4E (0.58) KDM4CKDM4EALDH1A1KMT2AL3MBTL1
SCHEMBL31584153 0.79 KDM4E (0.58) KDM4CKDM4EALDH1A1KMT2AL3MBTL1
SCHEMBL31207927 0.79 KDM4C (0.44) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL26600023 0.79 KDM4C (0.44) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL9000522 0.78 KDM4C (0.50) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL21063712 0.77 CYP11B1 (0.52) KDM4CKDM6BKDM4DKDM4EKDM4A
SCHEMBL21056630 0.77 CYP11B1 (0.52) KDM4CKDM6BKDM4DKDM4EKDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 — — US disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 — — US disclosed
US-11780821-B2 Inhibitors of fibroblast activation protein Praxis Biotech LLC (US) 2023-10-10 — — US disclosed
CN-112105354-A Fibroblast activation protein inhibitor 普拉西斯生物技术有限责任公司 2020-12-18 — — CN disclosed
EP-3723753-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2020-10-21 — — EP disclosed
WO-2019118932-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC (US) 2019-06-20 — — WO disclosed
US-20190185451-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC 2019-06-20 — — US disclosed
US-20190185451-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN Praxis Biotech LLC 2019-06-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190185451-A1 INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FAP, FIBP, FRS2 KDM4C 3750/4885KDM6B 2799/4885KDM4D 3469/4885
US-11780821-B2 Inhibitors of fibroblast activation protein FAP, FIBP, FRS2 KDM4C 3750/4885KDM6B 2799/4885KDM4D 3469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback